Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS
Benito Blanco Gómez,
Rubén López-Cortés,
Francisco Javier Casas-Nebra,
Sergio Vázquez-Estévez,
Daniel Pérez-Fentes,
María del Pilar Chantada-Vázquez,
Susana B. Bravo,
Cristina Núñez
Affiliations
Benito Blanco Gómez
Urology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Rubén López-Cortés
Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Francisco Javier Casas-Nebra
Urology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Sergio Vázquez-Estévez
Oncology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Daniel Pérez-Fentes
Urology Division, University Clinical Hospital of Santiago de Compostela (CHUS), Servizo Galego de Saúde (SERGAS), ES15706 Santiago de Compostela, Spain
María del Pilar Chantada-Vázquez
Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Susana B. Bravo
Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), ES15706 Santiago de Compostela, Spain
Cristina Núñez
Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), ES27002 Lugo, Spain
Because cystoscopy is expensive and invasive, a new method of detecting non-invasive muscular bladder cancer (NMIBC) is needed. This study aims to identify potential serum protein markers for NMIBC to improve diagnosis and to find treatment approaches that avoid disease progression to a life-threatening phenotype (muscle-invasive bladder cancer, MIBC). Here, silver nanoparticles (AgNPs, 9.73 ± 1.70 nm) as a scavenging device together with sequential window acquisition of all theoretical mass spectra (SWATH-MS) were used to quantitatively analyze the blood serum protein alterations in two NMIBC subtypes, T1 and Ta, and they were compared to normal samples (HC). NMIBC’s analysis of serum samples identified three major groups of proteins, the relative content of which is different from the HC content: proteins implicated in the complement and coagulation cascade pathways and apolipoproteins. In conclusion, many biomarker proteins were identified that merit further examination to validate their useful significance and utility within the clinical management of NMIBC patients.